GALLOWAY CHRISTOPHER D 4
4 · Diffusion Pharmaceuticals Inc. · Filed Mar 4, 2021
Insider Transaction Report
Form 4
GALLOWAY CHRISTOPHER D
Chief Medical Officer
Transactions
- Award
Stock Option (Right to Buy)
2021-03-01+27,180→ 27,180 totalExercise: $1.11Exp: 2031-03-01→ Common Stock (27,180 underlying) - Award
Stock Option (Right to Buy)
2021-03-01+81,537→ 81,537 totalExercise: $1.11Exp: 2031-03-01→ Common Stock (81,537 underlying)
Footnotes (2)
- [F1]The shares of common stock underlying the award will vest in 36 equal (or as near equal as possible) monthly installments on the last calendar day of each month over a 36-month period commencing March 31, 2021.
- [F2]The amount reported reflects the maximum number of shares of common stock underlying the award that may vest based upon the achievement of specified performance metrics. The vesting of such shares is contingent upon the timely and successful achievement during the year ending December 31, 2021 of certain performance milestones related to the Issuer's planned clinical trials, with the vesting of one-third (1/3) of the total shares tied to each such milestone. If any such milestone is achieved, one-third (1/3) of the shares tied to such milestone (i.e. one-ninth (1/9) of the total shares underlying the award) will vest immediately and the remainder of the shares tied to such milestone (i.e. two-ninths (2/9) of the total shares underlying the award) will vest in 24 equal (or as near equal as possible) monthly installments on the last calendar day of each month over a 24-month period commencing January 31, 2022. In order for all shares underlying the award to vest, all three milestones mus